Pernicious Anaemia
BMJ 369:m1319, Mohamed, M.,et al, 2020
Chronic Heart Failure and Ischemic Stroke
Stroke 42:2977-2982, Haeusler, K.G.,et al, 2011
LMNA Cardiomyopathy:Cell Biology and Genetics Meet Clinical Medicine
Disease Models & Mechanisms 4:562-568, Lu,J.T., et al, 2011
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Severe Cardiac Failure in a Patient with Multiple Sclerosis Following Low-Dose Mitoxantrone Treatment
Neurol 73:991-993, D�rr,J.,et al, 2009
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Clinical Relevance of Atrial Fibrillation/Flutter, Stroke, Pacemaker Implant, and Heart Failure in Emery-Dreifuss Muscular Dystrophy
Stroke 34:901-908, Boriani,G.,et al, 2003
Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002
Stroke in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction
Neurol 54:288-294, Pullicini,P.M.,et al, 2000
Treatment of End Stage Dilated Cardiomyopathy
Br Heart J 72:S52-S56, O'Connell,J.B.,et al, 1996
Predictors of Thromboembolism in Atrial Fibrillation:I. Clinical Features of patients at Risk
The Stroke Prevention in A Fib Investigators, Ann Int Med 116:1-51992., , 1992